20 analysts have shared their evaluations of Eli Lilly and Co LLY during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 16 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 11 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Eli Lilly and Co, revealing an average target of $799.0, a high estimate of $1000.00, and a low estimate of $630.00. This current average reflects an increase of 12.89% from the previous average price target of $707.75.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Eli Lilly and Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $850.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $850.00 | $775.00 |
| Geoff Meacham | B of A Securities | Raises | Buy | $1000.00 | $800.00 |
| Elmar Kraus | DZ Bank | Announces | Hold | $820.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $950.00 | $805.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Robyn Karnauskas | Truist Securities | Raises | Buy | $850.00 | $650.00 |
| David Phung | Morgan Stanley | Raises | Overweight | $805.00 | $763.00 |
| Geoff Meacham | Barclays | Raises | Overweight | $810.00 | $680.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $825.00 | $700.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $865.00 | $710.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $825.00 | $700.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $815.00 | $630.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $700.00 | $650.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
| Carter Gould | Barclays | Raises | Overweight | $680.00 | $630.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly and Co. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly and Co compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Eli Lilly and Co's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into Eli Lilly and Co's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Eli Lilly and Co analyst ratings.
Get to Know Eli Lilly and Co Better
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Insights: Eli Lilly and Co
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Eli Lilly and Co's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 28.1%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly and Co's net margin excels beyond industry benchmarks, reaching 23.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly and Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.59%, the company showcases effective utilization of assets.
Debt Management: Eli Lilly and Co's debt-to-equity ratio surpasses industry norms, standing at 2.34. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
